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Abstract 17 
In the early 1960s, Professor William F.H. Jarrett was presented with a time-space 18 
cluster of cats with lymphoma by a local veterinary practitioner, Harry Pfaff, and carried out 19 
experiments to find if the condition might be caused by a virus, similar to lymphomas noted 20 
previously in poultry and mice. In 1964, the transmission of lymphoma in cats and the 21 
presence of virus-like particles in the induced tumours that bore a striking resemblance to ‘the 22 
virus of murine leukaemias’ was reported in Nature. These seminal studies launched the field 23 
of feline retrovirology and research on the virus that had been identified and subsequently 24 
named ‘feline leukaemia virus’ (FeLV). This review considers the way in which some of the 25 
key early observations made by Professor Jarrett and his coworkers have developed over the 26 
years and provides an insight into the substantial progress that has been made since the virus 27 
was first discovered. 28 
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An introduction to feline leukaemia virus 33 
It is thought that the first felid-like carnivores evolved approximately 35 million years 34 
ago during the Oligocene epoch. The earliest fossil records of the Felinae date from the late 35 
Miocene epoch approximately 9 million years ago with remnants of the now extinct Felis 36 
attica from Eurasia (de Beaumont, 1964); however the domestic cat lineage, the genus Felis, 37 
appeared closer to 6.2 million years ago during the late Miocene epoch (Johnson et al., 2006). 38 
Some time after the emergence of the Felis, there appears to have been trans-species infection 39 
with gammaretroviruses of rodent origin, giving rise to the ancestral feline leukaemia virus 40 
(FeLV). 41 
 42 
Nucleic acid sequences related to ancestral FeLVs are present in the genomes of both 43 
domestic cats and closely related members of the genus Felis with their origins in the 44 
Mediterranean basin, including the jungle cat (F. chaus), sand cat (F. margarita) and 45 
European wildcat (F. sylvestris), but are absent from other members of the genus from sub-46 
Saharan Africa, Southeast Asia and the Americas, e.g. Geoffroy’s cat (F. geoffroyi) and the 47 
Serval (F. serval) (Benveniste et al., 1975). FeLV is now a widespread pathogen of the 48 
domestic cat and is distributed worldwide. Befitting its zoonotic origins, the virus has recently 49 
crossed genera once again, into the Florida panther (P. concolor) and the Iberian Lynx (L. 50 
pardinus) (Brown et al., 2008; Cunningham et al., 2008; Luaces et al., 2008; Meli et al., 2009, 51 
2010). 52 
 53 
 Like all retroviruses, FeLV is unstable in the environment and thus transmission is 54 
thought to require intimate contact between animals; whether friendly contacts such as 55 
grooming, or through fighting and biting (Francis et al., 1977, 1979a and b). A possible 56 
exception to the received wisdom is the finding that FeLV may be shed in urine and faeces 57 
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and that the shed virus retains the potential for transmission, presenting a theoretical risk of 58 
infection (Gomes-Keller et al., 2009). 59 
 60 
Following transmission, the course of infection may follow either of two paths. Most 61 
commonly, the exposed cat recovers and becomes solidly immune. However, in a lesser 62 
proportion of infected cats, the virus establishes a persistent infection that is marked by a 63 
viraemia and which is associated with an increased likelihood of developing a severe and 64 
ultimately fatal disease. The diseases associated with persistent infection are primarily 65 
disorders of haematopoiesis such as lymphomas and leukaemias, immune suppression and 66 
degenerative conditions including anaemia. During the prolonged viraemic phase, the animal 67 
may present as ostensibly healthy and thus may transmit infection to naïve recipients through 68 
virus shed in saliva (Francis et al., 1977; Gomes-Keller et al., 2006). Fortunately, diagnostic 69 
tests are available that can detect viraemic cats, facilitating their identification and isolation. 70 
Moreover, susceptible cats can be protected from infection by administration of one of the 71 
many highly efficacious recombinant FeLV vaccines that are currently available. 72 
 73 
Biology and replication of feline leukaemia virus 74 
FeLV belongs to the genus Gammaretrovirus, together with retroviruses of rodents, 75 
gibbons and koalas. The genetic information of retroviruses is encoded by an RNA genome 76 
and the first stage in the viral replicative cycle involves the copying of this RNA genome into 77 
a DNA copy. This process is performed by reverse transcriptase, the enzyme that is the target 78 
of anti-retroviral drugs such as AZT (azidothymidine, Zidovudine) and d4T (2'-3'-didehydro-79 
2'-3'-dideoxythymidine, Stavudine). Reverse transcriptase subverts the normal cellular flow of 80 
genetic information from DNA to RNA to protein. Once a DNA copy of the RNA genome has 81 
been synthesised, it integrates into the genome of the target cell as a provirus, assisted by a 82 
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second viral enzyme, the ‘integrase’. This provirus remains in the genome of the cell for the 83 
lifespan of the cell and, upon cellular division, the provirus is expressed, leading to the 84 
production of progeny virions and virus shedding. 85 
 86 
It is this unique property of retroviruses that renders them so difficult to eradicate 87 
completely from the infected host; a ‘latent’ infection may persist where the virus remains 88 
integrated into the genome of cells. Accordingly, both ‘recovered’ cats and solidly immune 89 
vaccinated cats may harbour integrated proviral genomes, but may never shed infectious 90 
virus; the cats are ‘protected’ from the development of viraemia and thus disease (Torres et 91 
al., 2005; Hofmann-Lehmann et al., 2008). 92 
 93 
Gammaretroviruses bud from the membrane of the infected cell, undergoing the final 94 
phase of maturation with cleavage of the of the Pr65Gag precursor into the mature structural 95 
proteins p15 MA, p27 CA and p10 NC. The capsid protein p27 forms the target for the 96 
majority of in-practice tests for FeLV, being abundant in the plasma of viraemic cats. 97 
However, its utility as a diagnostic for FeLV viraemia is only possible because cats do not 98 
appear to respond serologically to the protein, an observation that has led to speculation that 99 
cats may be largely immunologically tolerant to p27 through exposure to endogenously 100 
expressed FeLV Gag proteins. 101 
 102 
 As they bud from the infected cell, nascent virions acquire the envelope glycoprotein 103 
Env, comprising the surface (SU) glycoprotein gp70 and transmembrane (TM) protein p15E. 104 
Gp70 is the target for neutralising antibodies in recovered cats and is an essential component 105 
of FeLV vaccines; a recombinant bacterially-expressed form of gp70 is the sole component of 106 
one highly effective sub-unit vaccine (Marciani et al., 1991). During the production of this 107 
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subunit vaccine, the entire gp70 plus 34 amino acids of the transmembrane domain p15E are 108 
expressed in bacteria and purified. As bacterially expressed proteins are not glycosylated, the 109 
recombinant protein is referred to as p45. 110 
 111 
The combination of p45, the bacterially expressed recombinant Env in aluminium 112 
hydroxide and QuilA adjuvant is sufficient to induce protective immunity in vaccinated 113 
animals. Immunologically, this would suggest that there is a humoral response directed 114 
against linear determinants on gp70 and/or a cellular immune response that confers immunity 115 
to infection. While immunised cats mounted a potent humoral response to the vaccine antigen, 116 
neutralising antibodies were detected in only a proportion of immunised cats prior to 117 
challenge; nevertheless, solid protection was conferred in all animals (Marciani et al., 1991). 118 
The absence of neutralising antibodies prior to challenge following vaccination with 119 
efficacious FeLV vaccines has been noted for other FeLV vaccine preparations (Hofmann-120 
Lehmann et al., 2007). 121 
 122 
Three major subgroups of feline leukaemia virus: A, B and C 123 
In addition to being the primary target for the protective humoral immune response, 124 
gp70 also bears the determinants of the viral subgroup. There are three major subgroups of 125 
FeLV: A, B and C. The three subgroups were identified by classical assays of viral 126 
interference in which prior infection of cells with one subgroup of FeLV prevented 127 
subsequent infection with murine sarcoma virus pseudotypes bearing an envelope 128 
glycoprotein of the same subgroup (Sarma and Log, 1973, 1977). 129 
 130 
Interference assays implied the existence of three distinct viral receptors on target 131 
cells. Thus in cells infected with a subgroup A virus, the subgroup A receptor would be either 132 
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obscured or down-regulated from the cell surface by interactions with endogenously-produced 133 
Env protein. These cells would be rendered refractory to infection with viruses bearing 134 
subgroup A Envs, but would remain susceptible to infection with viruses bearing the 135 
subgroups B or C Envs. 136 
 137 
Using this simple technique, major advances were made in our understanding of the 138 
role of the viral subgroups in the pathogenesis of FeLV associated disease. For example, 139 
FeLV-A is the most abundant form of the virus in nature and is the virus that is responsible 140 
for transmission between animals (Jarrett and Russell 1978; Jarrett et al., 1978). Thus, 141 
vaccination against subgroup A virus is the sole requirement for inducing immunity to 142 
infection. 143 
 144 
The two other subgroups of virus, subgroups B and C, arise in subgroup A infected 145 
cats following the establishment of a viraemia. The generation of FeLV-B occurs following 146 
recombination between the exogenous FeLV-A and endogenously expressed FeLV Env 147 
encoding transcripts (Stewart et al., 1986; Overbaugh et al., 1988). Much has been learned 148 
about the recombination breakpoints and the genomic loci responsible for generating 149 
subgroup B viruses (Roy-Burman, 1995); the process of recombination between exogenous 150 
FeLV-A and endogenous FeLV sequences that occurs in vivo has been reproduced in vitro 151 
(Sheets et al., 1992). 152 
 153 
The precise site of recombination between FeLV-A and endogenous FeLV in the 154 
infected cat is unknown. Previous studies have demonstrated the presence of endogenous 155 
FeLV transcripts in the feline placenta (Busch et al., 1983) and in the thymus and lymph 156 
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nodes of specific-pathogen free cats (McDougall et al., 1994); thus viral replication at these 157 
sites would offer an opportunity for recombination to occur. 158 
 159 
As the level of endogenous FeLV transcripts expressed in peripheral blood varies 160 
between distinct cat populations and is influenced by breed and gender (Tandon et al., 2007), 161 
the likelihood of subgroup B viruses arising in vivo may vary from cat to cat. Early 162 
experiments by Bill Jarrett and his colleagues into the association between viral subgroups 163 
and disease outcomes demonstrated that cats that were viraemic with FeLV-A and FeLV-B 164 
were at a higher risk of developing lymphoma than cats with FeLV-A alone. 165 
 166 
With his expertise in animal and human pathology, and his knowledge of neoplastic 167 
diseases of haematopoietic and lymphoid tissues (Jarrett and Mackey, 1974), Bill Jarrett 168 
observed a predominance of T cell lymphomas in FeLV-infected cats, inspiring the U.S. 169 
biomedical researcher Robert Gallo to search for a viral agent associated with human T cell 170 
leukaemias. These studies led to the discovery of human T cell leukaemia virus type I and 171 
subsequently human immunodeficiency virus type 1. 172 
 173 
 The third viral subgroup, FeLV-C, arises infrequently in viraemic cats and is only 174 
isolated from cats with disease (Jarrett et al., 1978). In a survey of the viral subgroups in 175 
naturally-infected viraemic cats, subgroup C viruses were not isolated from 98 clinically 176 
normal cats, but were identified in samples from 9/32 anaemic cats surveyed (Onions et al., 177 
1982). The genesis of subgroup C viruses in the infected animal has yet to be ascertained. 178 
Molecular analyses have demonstrated that FeLV-Cs have unique receptor binding domain 179 
sequences in gp70 that are suggestive of a mutational rather than recombinatorial origin 180 
(Riedel et al., 1986; Rigby et al., 1992). FeLV-Cs are not transmitted between cats; rather 181 
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they arise de novo in viraemic animals. Following their emergence in vivo, FeLV-Cs give rise 182 
to pure red cell aplasia, an anaemia that may prove fatal within weeks. 183 
 184 
Cellular receptors for feline leukaemia virus 185 
The virus-receptor interaction is the primary determinant of cell tropism and 186 
contributes significantly to the pathogenesis of disease. Accordingly, the cell tropism of the 187 
three major subgroups of FeLV is determined by the expression patterns of their respective 188 
receptors; FeLV-A Env binds to target cells through an interaction with the thiamine 189 
transporter THTR1 (Mendoza et al., 2006), FeLV-B attaches via a phosphate symporter Pit-1 190 
(O'Hara et al., 1990; Johann et al., 1992; Takeuchi et al., 1992) and the closely-related 191 
molecule Pit-2 (Anderson et al., 2001), while FeLV-C utilises a haem transporter FLVCR1 192 
for viral entry (Tailor et al., 1999; Quigley et al., 2000) (Fig. 2). 193 
 194 
THTR1 is expressed widely in feline tissues, consistent with the broad cellular tropism 195 
of FeLV-A (Mendoza et al., 2006). In contrast, although the subgroup C receptor FLVCR1 is 196 
expressed widely in haematopoietic tissues (Tailor et al., 1999), its function in the export of 197 
cytoplasmic haem would appear to be essential for the development of erythroid progenitors, 198 
protecting them from haem toxicity (Quigley et al., 2004). Perturbation of this essential 199 
function of FLVCR1 in erythroid progenitor cells results in the selective loss of colony 200 
forming units-erythroid, CFU-E, and the development of a severe non-regenerative anaemia. 201 
 202 
Thus the seemingly esoteric endeavour of identifying the cellular receptor for FeLV-C 203 
has revealed the biochemical basis for the pathological changes described by Hoover et al. 204 
(1974) in the bone marrow of cats infected with the KT strain of FeLV (Kawakami et al., 205 
1967) that was subsequently shown to be a mixture of subgroups A, B and C, as well as by 206 
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Mackey et al. (1975) following inoculation of cats with the first isolate of FeLV-C. FLVCR1 207 
was the first mammalian haem transporter to be described (Quigley et al., 2004). 208 
 209 
The similarities between FeLV-C-associated pure red cell aplasia and Diamond 210 
Blackfan anaemia, a rare inherited blood disorder that is characterised by moderate to severe 211 
reduction in the production of erythroid progenitor cells, stimulated interest in a role for the 212 
human orthologue of FLVCR in Diamond Blackfan anaemia. Subsequent studies revealed 213 
that a defect in splicing of the human FLVCR1 gene associated with mutations in the RPS19 214 
gene (Willig et al., 1999; Draptchinskaia et al., 1999) disrupts FLVCR1 expression and 215 
contributes to the failure of erythropoeisis in Diamond Blackfan anaemia (Rey et al., 2008), 216 
illustrating the value of such comparative studies. 217 
 218 
FLVCR1 is not the only receptor for FeLV-C; just as FeLV-B can utilise the closely 219 
related Pit-1 and Pit-2 molecules for infection, some strains of FeLV-C can infect through an 220 
interaction with FLVCR2 (Shalev et al., 2009). Like FLVCR1, FLVCR2 is a transporter of 221 
haem, although its function is in importation of haem (Duffy et al., 2010). Together, the 222 
human orthologues of FLVCR1 and FLVCR2 appear to play critical roles in haemostasis. 223 
Recently, mutations in FLVCR2 have been found to be associated with Fowler-syndrome 224 
(Meyer et al., 2010), a proliferative vascular disorder of the brain. 225 
 226 
At present there is no direct evidence to suggest that an impairment of THTR1 227 
function in cats by FeLV-A replication contributes to the diseases that are associated with 228 
FeLV-A infection, however it is worthy of note that mutations in the human orthologue of 229 
THTR1 are responsible for a thiamine responsive megaloblastic anaemia known as Rogers 230 
syndrome (Labay et al., 1999). It is intriguing that one of the earliest studies on the 231 
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association between FeLV subgroups and the development of anaemia observed that subgroup 232 
A and subgroup C viruses induced distinct anaemias; while FeLV-C induced an aplastic 233 
anaemia, infection with a subgroup A virus resulted in a macrocytic anaemia associated with 234 
increased erythropoeisis (Mackey et al., 1975). 235 
 236 
Transmission and pathogenesis 237 
The original transmission experiments with ‘cat leukaemia’ were attempted because 238 
Bill Jarrett found a cluster of eight cases in a single household of unrelated cats (Jarrett, 239 
1972). Subsequent epidemiological studies by researchers in the U.S. indicated that the 240 
introduction of an infected male cat into households for breeding purposes led to the 241 
establishment of infection within the household (Brodey et al., 1970), while housing 242 
uninfected kittens with infected kittens led to the spread of the virus (Rickard, 1969). 243 
Together, these findings suggested to Bill Jarrett that the virus was transmitted horizontally 244 
and therefore he conducted a series of experiments which proved that virus transmission 245 
occurred between in-contact animals and that physical separation prevented infection, 246 
consistent with horizontal transmission (Jarrett, 1972; Jarrett et al., 1973). 247 
 248 
The primary route by which FeLV is transmitted is thought to be via oro-nasal 249 
exposure to virus-containing secretions. High levels of FeLV are present in the saliva of 250 
viraemic cats (Francis et al., 1977, 1979a; Gomes-Keller et al., 2006) but as the virus is 251 
relatively labile in the environment (Francis et al., 1979b), it is thought that intimate contact 252 
between animals during grooming, sharing feeding bowls or through fighting are the most 253 
likely routes of transmission. 254 
 255 
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The application of highly sensitive molecular techniques to the detection of FeLV 256 
RNA in secretions have confirmed the link between the level of plasma viraemia and the 257 
amount of virus shed in secretions (Gomes-Keller et al., 2006, 2009); thus a viraemic cat is 258 
more likely to transmit virus than a cat that has recovered from infection. Whether a cat 259 
recovers from infection or develops viraemia and ultimately develops disease is governed by a 260 
number of factors at the time of transmission. One of the key determinants of susceptibility to 261 
infection is the age of the cat at the time of exposure (Hoover et al., 1976); only 15% of cats 262 
aged between 4 months and 1 year of age became persistently viraemic following 263 
experimental infection, while 85% of cats between 2 and 8 weeks of age became infected 264 
following challenge (Hoover et al., 1976). 265 
 266 
The rapid development of resistance to infection appeared to be immune related, since 267 
immunosuppression with either corticosteroids or methylnitrosourea abrogated the age-related 268 
resistance (Rojko et al., 1979; Schaller et al., 1978). Recovery from infection is associated 269 
with a marked reduction in plasma viraemia, such that virus may no longer be isolated from 270 
plasma and virus neutralising antibodies (VNAs) are detected. Recovered cats may also be 271 
referred to as having ‘regressive’ infections, while viraemic cats have ‘progressive’ infections. 272 
 273 
It is likely that it is the ability of the majority of cats to recover from natural exposure 274 
to FeLV that underlies the success of many FeLV vaccines; if 85% of cats between 4 months 275 
and 1 year of age recover naturally, then vaccination may simply tip the balance in favour of 276 
recovery by priming the immune system to generate robust cellular and/or humoral responses. 277 
In support of this hypothesis, most animals vaccinated in an experimental setting do not 278 
generate VNAs until after viral challenge, suggesting the induction of an anamnestic 279 
response. 280 
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 281 
A proportion of cats which recover from natural infection with FeLV harbour 282 
infectious virus in their bone marrow (Madewell and Jarrett, 1983; Rojko et al., 1982). This 283 
state of latency can be reversed by immunosuppressive treatment with corticosteroids (Rojko 284 
et al., 1979). The application of sensitive molecular techniques, such as quantitative real-time 285 
PCR has provided further insight into the nature of the process of natural recovery from 286 
infection, leading to the suggestion that the spectrum of outcomes following infection may 287 
require further refinement (Torres et al., 2005; Hofmann-Lehmann et al., 2006, 2007, 2008). 288 
 289 
The absence of FeLV proviral DNA after challenge indicates an ‘abortive’ infection, 290 
which is distinct from a ‘regressive’ infection, where a transient antigenaemia is followed by 291 
the establishment of low to moderate proviral loads (Hofmann-Lehmann et al., 2006, 2008). 292 
Animals that recovered from infection and which tested negative for viral antigen in plasma, 293 
but maintained detectable levels of plasma viral RNA, were considered to be at a higher risk 294 
for reactivation of the latent infection than cats which had undetectable plasma viral RNA 295 
following recovery (Hofmann-Lehmann et al., 2007). In contrast, viraemic cats were 296 
considered to have a progressive infection and this was marked by persistently high plasma 297 
viral RNA loads. 298 
 299 
Data regarding latently infected cats have been conflicting, while one study reported 300 
the presence of detectable proviral DNA and plasma viral RNA (Torres et al., 2005), a second 301 
study found no difference in viral and proviral loads between latently infected cats and cats 302 
with a regressive infection with no latent infection (Hofmann-Lehmann et al., 2007). Given 303 
the discrepant findings, we would support the retention of the definition of a ‘latent’ infection 304 
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as the absence of virus/viral antigen in blood in the presence of reactivatable virus in the bone 305 
marrow (Rojko et al., 1982; Madewell and Jarrett, 1983; Hofmann-Lehmann et al., 2008). 306 
 307 
Evidence suggests that the latent state is transitory and that, with time, the majority of 308 
latently infected cats will ultimately clear the virus from their bone marrow. In a follow-up of 309 
the seminal study on viral latency (Madewell and Jarrett, 1983), it was noted that, by 3 years 310 
post-infection, only 8% of recovered cats with VNAs still harboured reactivatable proviruses 311 
in their bone marrow (Pacitti and Jarrett, 1985). Cats which have recovered from FeLV 312 
infection have a similar life expectancy to cats that have never been exposed to FeLV, 313 
suggesting that a latent infection with FeLV does not predispose the cat to the development of 314 
FeLV-associated disease. 315 
 316 
Vaccination against feline leukaemia virus 317 
Ten years after the first description of FeLV, Bill Jarrett published the first reports 318 
describing experimental vaccination against FeLV (Jarrett et al., 1974, 1975). This first 319 
approach to vaccination relied upon the ability to maintain FeLV-infected cells in culture. 320 
Initially, animals were inoculated with either FeLV-infected feline fibroblasts or lymphoblasts 321 
and strong humoral responses were induced in either naïve cats or cats previously exposed to 322 
FeLV (Jarrett et al., 1974). A refinement of the approach used paraformaldehyde inactivated 323 
cells (derived from FL74 lymphosarcoma cells; Theilen et al., 1969) to remove the possibility 324 
of an infection being established by the vaccine (Jarrett et al., 1975). 325 
 326 
Subsequent studies demonstrated that the proportion of cats challenged with FeLV that 327 
became viraemic could be reduced by vaccination with inactivated whole virus derived from 328 
FL74 cells (Pedersen et al., 1979), while concentrated envelope glycoprotein purified from the 329 
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culture fluid of FL74 cells was sufficient to protect against viraemia, most strikingly when 330 
combined with a potent adjuvant (Lewis et al., 1981). By 1985, 10 years from the first 331 
experimental inactivated FeLV-infected cell vaccine, the subunit approach to vaccination had 332 
been refined, with the incorporation of the viral gp70/85 into immune stimulating complexes 333 
(ISCOMs), resulting in the FeLV ISCOM vaccine that protected 100% of cats from viraemia 334 
following challenge with FeLV (Osterhaus et al., 1985). 335 
 336 
 FeLV vaccines have continued to advance over recent years with three main families 337 
of vaccine available commercially: (1) classical inactivated virus vaccines, the technology 338 
behind which has changed very little over the intervening years; (2) subunit vaccines based on 339 
bacterially-produced envelope glycoprotein, gp70 (Marciani et al., 1991); and (3) a live 340 
recombinant canary-pox virus engineered to express FeLV genes (Tartaglia et al., 1993; 341 
Poulet et al., 2003). 342 
 343 
As indicated above, perhaps the most surprising vaccine success has been the 344 
bacterially-produced gp70. When Bill Jarrett and colleagues described their first attempts at 345 
FeLV vaccination, infected cells were used because it was ‘considered likely that the integrity 346 
of the glycoprotein complexes which are effective immunogens might be well preserved’ 347 
(Jarrett et al., 1975). This would seem an entirely rational approach to vaccine design. One of 348 
the most successful vaccines developed subsequently was the FeLV-ISCOM vaccine which 349 
relied on the incorporation of fully glycosylated protein into a complex matrix that ensured 350 
delivery of the gp70 to antigen-presenting cells in a conformation that would reflect that on 351 
the native virion (Osterhaus et al., 1985). 352 
 353 
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That a non-glycosylated, bacterially-produced Env protein bearing a C-terminal 354 
truncation should protect cats from viraemia (Marciani et al., 1991) must reveal a great deal 355 
about the nature of immunity to FeLV. The majority of older cats recover from FeLV 356 
infection; vaccination may simply prime cats such that recovery is more likely, if not the sole 357 
outcome following challenge. VNAs are seldom induced prior to challenge; however the 358 
development of VNAs following challenge is a consistent feature of vaccine induced 359 
recovery. The majority of studies suggest that sterilising immunity is seldom induced by 360 
vaccination, that a minimal level of viral replication occurs in the vaccinated cat and that this 361 
results in proviral integration. However, the vaccinated cat is protected from the development 362 
of viraemia and thus will neither shed nor transmit virus, becoming, effectively, a dead-end 363 
host for FeLV. 364 
 365 
 Significant concerns have been raised regarding over-vaccination of companion 366 
animals and, in particular, the occurrence of vaccine-associated injection site sarcomas in cats. 367 
It is thought that a potent local inflammatory response at the injection site may predispose the 368 
animals to the development of soft-tissue sarcomas and thus both strong adjuvants and 369 
immunogens have been postulated to play a role. 370 
 371 
In order to circumvent the need for strong adjuvants, whilst still inducing robust 372 
humoral and cellular immunity, a canary pox (ALVAC) vectored FeLV vaccine has been 373 
developed (Tartaglia et al., 1993). ALVAC-FeLV is a replication defective live virus vaccine 374 
and thus presents antigen through both the endogenous and exogenous pathways, ensuring the 375 
induction of both cellular and humoral immunity. Significantly, ALVAC-FeLV does not 376 
require an adjuvant to induce protection from both viraemia and latency (Poulet et al., 2003). 377 
Moreover, the large genome of the poxvirus vector allows the incorporation of both gag and 378 
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env gene products, ensuring a broad antiviral immune response is induced. Given that 379 
previous studies have indicated a role for cytotoxic T cells in immunity to FeLV infection 380 
(Flynn et al., 2000, 2002), the presentation of T cell epitopes in both Gag and Env from a 381 
vectored virus vaccine may prove beneficial in inducing long-lasting immunity and 382 
facilitating the efficient clearance of virus-infected cells. 383 
 384 
Diagnosing feline leukaemia virus infection 385 
The control of FeLV in a population of cats may be achieved by a combination of 386 
isolating infected cats whilst vaccinating susceptible cats; it is recommended that at risk cats 387 
be tested prior to vaccination against FeLV. Early studies by Bill Jarrett demonstrated the 388 
presence of antibodies in the sera of cats that reacted with feline-oncornavirus-associated cell 389 
membrane antigens (FOCMA) and that this reactivity could be used to assess the prevalence 390 
of FeLV in a cat population (Jarrett et al., 1973). Accordingly, he was able to show that, in 391 
Glasgow, approximately 40% of cats had been exposed to FeLV, whereas the actual incidence 392 
of leukaemia in the population was closer to 0.05%, suggesting that the majority of cats 393 
exposed to FeLV recover from infection. These studies complemented those in which ‘group-394 
specific’ or ‘type-specific’ reagents were used to demonstrate the presence of viral antigens in 395 
leukocytes (Hardy et al., 1973). 396 
 397 
The majority of in-practice tests for FeLV in current use detect viral antigen in blood, 398 
whether whole blood, plasma or serum. The antigenic target for these tests is the viral capsid 399 
protein p27, the viral protein that is most abundant in the plasma of viraemic cats. Most in 400 
practice tests are based on the principle of rapid immunomigration (immunochromatography). 401 
These tests tend to be of high specificity, detecting near to 100% of antigenaemic cats. The 402 
sensitivity of these tests is less reliable; a proportion of FeLV-infected cats (regressive 403 
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infections) will be antigen-negative and be undetected by antigen-based tests. Detection of 404 
these cats relies on more sensitive techniques using PCR and many diagnostic laboratories 405 
now offer real-time PCR for the quantification of FeLV proviral DNA and viral RNA. 406 
 407 
Quantifying proviral DNA enables the diagnostic laboratory to identify recovered cats 408 
(regressive infection) in which the viraemia has been cleared but where proviral DNA may 409 
remain integrated into the genome of cells within the bone marrow or lymphoid tissues 410 
(Torres et al., 2005; Hofmann-Lehmann et al., 2008). In contrast, real-time PCR for viral 411 
RNA is effectively measuring levels of virus in plasma or secretions that are below the 412 
sensitivity of tests for viral antigen. Accordingly, it may be possible to detect very low levels 413 
of virus in saliva where conventional antigen tests have proved negative (Gomes-Keller et al., 414 
2006). Either test may be of value in ascertaining the biological basis for discordant p27 415 
antigen tests, for example sporadic weak p27 positive tests or borderline positive tests may 416 
indicate a latent infection in the bone marrow. Real-time PCR testing may be used to confirm 417 
the presence of an infection while quantifying the viral load. 418 
 419 
 Following a confirmed diagnosis of infection, infected animals should be isolated 420 
from susceptible cats to prevent the spread of infection. Testing susceptible cats for evidence 421 
of spread will allow the introduction of a vaccination program for the at-risk animals in order 422 
to curtail the spread of the virus. Through rigorous testing, vaccination and through the 423 
isolation of infected animals, levels of FeLV infection in many parts of Europe have 424 
decreased markedly (Lutz et al., 2009). 425 
 426 
Conclusions 427 
 19 
In 2011, veterinary science lost one of its great investigators. There are many 428 
significant scientific breakthroughs in which Bill Jarrett was at the forefront. For us, he will 429 
be best remembered for his ground-breaking studies on FeLV. He established a FeLV 430 
laboratory which over many years attracted a cohort of scientists who investigated many 431 
aspects of the biology of FeLV and established systems that have almost eliminated the virus 432 
from the UK. 433 
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Figure legends 765 
 766 
Fig. 1. The assembly of feline leukaemia virus (FeLV) at the plasma membrane. The 767 
precursor of the viral structural proteins Pr65Gag is thought to attach to the underside of the 768 
membrane via an interaction between N-terminal myristate and membrane phospholipids. 769 
Once bound, the Pr65Gag proteins multimerise, triggering the membrane to bend around the 770 
forming core. Env proteins associate with the nascent particle through their co-localisation on 771 
the membrane until an immature particle is formed. A scission event then takes place 772 
releasing the immature virion into the extracellular milieu, at which time the viral protease 773 
cleaves Pr65Gag into distinct MA, CA and NC proteins. Inset: Electron micrograph of two 774 
FeLV particles in a vesicle within a mesenteric lymph node cell, from Bill Jarrett’s seminal 775 
study (Jarrett et al., 1964).  776777 
 778 
Fig. 2. The cellular receptors for feline leukaemia virus (FeLV): (1) FeLV-A; (2) FeLV-B; 779 
and (3) FeLV-C. The three viral receptors have different transport functions and thus 780 
perturbation of their function by FeLV may result in distinct clinical manifestations. 781 
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